Vogenx (NASDAQ:VOGX – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research note issued to investors on Monday, Zacks reports.
Other research analysts have also issued research reports about the company. WBB Securities initiated coverage on Vogenx in a research report on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 target price for the company. Wall Street Zen raised Vogenx to a “hold” rating in a research note on Saturday, August 22nd. Finally, JonesTrading assumed coverage on Vogenx in a research report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Vogenx presently has an average rating of “Buy” and a consensus price target of $48.50.
View Our Latest Report on VOGX
Vogenx Price Performance
Vogenx (NASDAQ:VOGX – Get Free Report) last released its quarterly earnings results on Thursday, September 17th. The company reported ($0.07) earnings per share for the quarter. Equities analysts anticipate that Vogenx will post -0.61 earnings per share for the current fiscal year.
Vogenx Company Profile
Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.
The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.
Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.
Further Reading
- Five stocks we like better than Vogenx
- Bitcoin Is Bouncing Back—Here are 2 Ways to Play the Rebound
- The Bull Case for Amprius Technologies Just Got Stronger
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.
